Here, we extend this analysis to test the efficacy of 2 new, potent, and selective SGK1-Is (SGK1-I1 and SGK1-I2) in additional patient-specific iPSC-CM models of LQT3 (SCN5A-P1332L and SCN5A-R1623Q) as well as determine for the first time the potential role of an SGK1-I–based treatment strategy for LQT1 and LQT2. Here, SCN5A is linked to long QT syndrome 3.